Zacks Research Issues Optimistic Estimate for CPRX Earnings

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Equities research analysts at Zacks Research boosted their Q2 2025 EPS estimates for Catalyst Pharmaceuticals in a report released on Wednesday, May 28th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn $0.52 per share for the quarter, up from their previous forecast of $0.51. The consensus estimate for Catalyst Pharmaceuticals' current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals' Q3 2025 earnings at $0.50 EPS, Q4 2025 earnings at $0.42 EPS, Q1 2026 earnings at $0.58 EPS, Q2 2026 earnings at $0.57 EPS, Q3 2026 earnings at $0.62 EPS and Q1 2027 earnings at $0.71 EPS.

Several other brokerages have also commented on CPRX. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Stephens reissued an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Robert W. Baird increased their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, March 3rd. Finally, HC Wainwright reissued a "buy" rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $32.29.

Catalyst Pharmaceuticals Stock Up 1.3%

Catalyst Pharmaceuticals stock traded up $0.31 during mid-day trading on Friday, hitting $24.89. The company had a trading volume of 2,081,400 shares, compared to its average volume of 1,110,361. The stock has a market cap of $3.04 billion, a price-to-earnings ratio of 21.09, a PEG ratio of 3.31 and a beta of 0.70. Catalyst Pharmaceuticals has a 1 year low of $14.75 and a 1 year high of $26.16. The business has a fifty day moving average of $23.57 and a 200 day moving average of $22.60.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This trade represents a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the firm's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. This represents a 39.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 351,879 shares of company stock worth $8,214,815 in the last three months. Insiders own 10.40% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC purchased a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at $27,000. Park Square Financial Group LLC purchased a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at $29,000. Sound Income Strategies LLC purchased a new position in shares of Catalyst Pharmaceuticals in the first quarter valued at $64,000. Farther Finance Advisors LLC increased its position in shares of Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after buying an additional 1,495 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after purchasing an additional 579 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.